Intec Pharma announces the preliminary results from a pharmacokinetic study comparing the company’s Accordion Pill Carbidopa/Levodopa 50/500mg dosed three times daily to 1.5 tablets of CD/LD immediate release 25/100 dosed five times per day in Parkinson’s disease patients. The company plans to submit the full data set for potential presentation and publication at a major medical meeting and in a peer review journal, respectively.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.